GLP-1: The Drug Rewrote the Rules
The research accumulating around GLP-1 medications has the quality of a map being redrawn while you're standing on it.
GLP-1: The Drug Rewrote the Rules
There is a particular kind of medical moment when a treatment stops being one thing and becomes something else entirely. Penicillin was supposed to treat wounds. Aspirin was supposed to reduce fever. And Ozempic was supposed to help people lose weight — which it does, but that is increasingly the least interesting thing about it.
The research accumulating around GLP-1 medications has the quality of a map being redrawn while you're standing on it. A study published in September found that tirzepatide — sold as Mounjaro — may reduce fracture risk in people with type 2 diabetes, a population where fragility fractures are common and often catastrophic. The mechanism appears to be indirect: better metabolic control, less inflammation, possibly improved bone density. Nobody designed Mounjaro to protect bones. It seems to be doing it anyway.
Meanwhile, GLP-1 use in American children under twelve has risen sharply, even though the FDA has not approved these medications for that age group. One in five children in the United States lives with obesity — a condition that carries real cardiovascular and cancer risk. The prescriptions are happening in the space between desperation and evidence, which is uncomfortable territory but not unfamiliar in medicine.
And then there is the shingles vaccine, which has nothing to do with GLP-1s and everything to do with how we underestimate what we already have. New research suggests that the recombinant shingles vaccine may reduce cardiovascular disease risk by nine percent. Nine percent sounds modest until you consider that this is a vaccine most adults in Malta could book through their GP and most haven't. The protection appears to come from reducing the chronic inflammation that shingles infection triggers — inflammation that, left unchecked, stresses the heart over years.
What connects these three findings is something I've been thinking about since a conversation in Geneva with a physician who said the future of medicine would not be dramatic breakthroughs but *unexpected adjacencies* — treatments doing things we didn't design them to do, protections arriving from directions we weren't watching. The body is a system. What quiets one fire often cools another. We are only beginning to map the connections.
The thing you can do: if you are over fifty and haven't had the shingles vaccine, book it. It takes one appointment, it costs very little, and the cardiovascular data is genuinely persuasive. Your heart may thank a decision that looked, on the surface, like it had nothing to do with your heart at all.
